Balderton Announces $1.3B in New Funds to Back Europe’s Top Entrepreneurs as They Build World-Changing Businesses
Balderton Capital, one of Europe’s leading technology venture capital firms, today announced its $615 million Early Stage Fund IX and $685 million Growth Fund II, to back Europe’s most ambitious entrepreneurs from seed stage through IPO.
“At Balderton, we believe the best way to change the world is to build a business - and that many of these world-changing businesses will be built in Europe,” said Bernard Liautaud, Managing Partner at Balderton. “As a firm, our mission is simple: to be the partner of choice to the founders starting and growing those European technology companies. These new funds put us in a position to do just that.”
There was strong investor demand for Early Stage Fund IX and Growth Fund II, which marked the first time Balderton raised its early and growth funds simultaneously. The increasingly global mix of LPs in the firm’s funds have been attracted to Balderton’s European focus and track record of success during its 25 year history. This includes one of the largest and most prominent public state pensions in the United States, building out a selective European VC portfolio, and British Patient Capital, the UK's largest domestic investor in venture and venture growth opportunities.
There is now a long and diverse history of Europe as a key hub for global tech, with proven winners across sectors and countries. In just the last two years, Europe has established itself as a leader in AI, with London and Paris being the key innovation centres. The reasons for this are not surprising or new: world class institutions and engineers, a growing culture of entrepreneurialism, a developed funding ecosystem and, increasingly, third and fourth generation founders.
The growth of the European technology ecosystem has created strong returns for investors as well. European VC funds outperformed North American funds over both a 10 and 15 year period, according to data from Invest Europe and Cambridge Associates.
Since its founding in 2000, Balderton has invested in more than 275 technology companies from across Europe. The current portfolio includes global category leaders like Revolut, Dream Games, GoCardless, Contentful, Aircall, Wayve, Writer and PhotoRoom. Many previous portfolio companies have successfully exited, such as Darktrace, Depop, MySQL, Peakon, Recorded Future, Talend and THG. Balderton’s investment history spans technology sectors including AI, fintech, B2B SaaS, digital health, mobility, gaming and marketplaces.
Beyond the hands-on support from its investment team, who have invaluable operational and entrepreneurial experience, Balderton offers a range of services to its founders and portfolio companies, including:
- The Balderton Platform team, comprising experts in legal, finance, talent and people, marketing and sustainability
- Executives in Residence - industry veterans with decades of experience as startup builders and operators, with expertise in areas including sales, engineering, product and legal
- The Balderton Community of more than 700 leading European technology executives from across the portfolio, who come together for peer support, networking and events, and form one of the strongest startup networks in Europe
In addition, Balderton takes unprecedented steps to support founders through its industry-leading Balderton Founder Wellbeing and Performance platform. This covers executive coaching, peer to peer support in CEO Forums, a health and fitness program and access to a digital platform for parent founders.
With Balderton’s 65 team members across Europe, $1.3bn in new funds, and a strong portfolio of more than 125 companies, the firm is excited to continue its work of partnering with Europe’s top entrepreneurs as they build world-changing companies.
About Balderton Capital
Balderton Capital is a multistage venture firm with more than two decades of experience supporting Europe’s best founders from Seed to IPO. We have both early and growth funds and invest across the technology sector, with a proven track record backing AI, fintech, B2B SaaS, digital health, mobility, gaming and marketplace companies. Previous investments include Darktrace (LON: DARK), Depop, Flywire (NASDAQ: FLYW), Kobalt, MySQL, Nutmeg, Peakon, Recorded Future, Talend (NASDAQ: TLND) and THG (LON: THG). Balderton’s current portfolio includes: Aircall, Beauty Pie, Contentful, Dream Games, GoCardless, Lendable, Matillion, Merama, Photoroom, Revolut, Tibber, Wayve, Writer and ZOE.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240808083911/en/
Contacts
India Phillips
iphillips@balderton.com
Sayula Kirby
sayula@burlington.cc
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mastering Complexity & Increasing Efficiency: CES 2026: dSPACE Demonstrates Test and AI Solutions for SDV Development16.12.2025 14:02:00 CET | Press Release
At CES 2026, dSPACE will showcase end-to-end test solutions that enable vehicle manufacturers to efficiently master the increasing complexity in the development of software-defined vehicles. At booth 4500 in West Hall, dSPACE will present a comprehensive validation portfolio with AI-supported software-in-the-loop and hardware-in-the-loop solutions for accelerated vehicle development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251216117958/en/ At CES 2026, dSPACE will present a comprehensive validation portfolio with AI-supported software-in-the-loop and hardware-in-the-loop solutions for accelerated SDV development. AI is a strategic enabler throughout the entire development and test process. dSPACE has been exploring how the latest developments in generative and agentic AI technologies can support software-in-the-loop (SIL) testing and enable CI/CD pipelines for automated validation. In an exhibit, dSPACE will demonstra
PPG achieves REDCert² sustainable raw material certification at two key European sites16.12.2025 14:01:00 CET | Press Release
PPG (NYSE: PPG) today announced that its Architectural Coatings manufacturing sites in Amsterdam, the Netherlands and Søborg, Denmark have received REDCert² certification, which verifies the use of sustainable raw materials through a certified chain of custody. REDCert² uses the mass balance approach, a recognized method for attributing the sustainability value of certified inputs. This ensures that PPG’s products reflect responsible sourcing throughout the manufacturing process and reinforces the company’s commitment to delivering high-performing, sustainably advantaged solutions to customers across Europe. “This certification supports our broader goal of integrating sustainability and productivity into our operations and our commitment to transparent manufacturing,” said Mats Hagerstrom, PPG head of sustainability, EMEA, Architectural Coatings. “It helps us deliver products that meet high performance standards while supporting our customers’ environmental objectives.” The certified s
FIFA World Cup™ Trophy Tour by Coca-Cola to Begin Global Journey Ahead of FIFA World Cup 2026™16.12.2025 14:00:00 CET | Press Release
The Coca-Cola Company and FIFA are kicking off the sixth FIFA World Cup™ Trophy Tour by Coca-Cola, giving thousands of fans across the globe the opportunity to see the original FIFA World Cup™ Trophy ahead of FIFA World Cup 2026™. FIFA World Cup 2026 is set to be the biggest yet—spanning three host nations, Canada, Mexico and the United States, with more teams, more matches and more celebrations than ever before. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251216393608/en/ FIFA World Cup™ Trophy Tour by Coca-Cola As a long-standing partner of FIFA, Coca-Cola has the exclusive rights to the FIFA World Cup Trophy Tour by Coca-Cola. Beginning Jan. 3, 2026, in Riyadh, Saudi Arabia, the original FIFA World Cup Trophy will visit 30 FIFA Member Associations across 75 stops and more than 150 tour days, giving fans around the world a once-in-a-lifetime chance to see football’s most coveted prize. "Football has an unmatched ability
1GLOBAL Empowers Revolut to Offer Mobile Plans in Poland16.12.2025 13:04:00 CET | Press Release
1GLOBAL, a technology-driven global mobile communications provider, strengthens its partnership with Revolut, expanding the leading neobank’s mobile data plan offering to the Polish market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251216769985/en/ 1GLOBAL strengthens its partnership with Revolut, expanding the leading neobank’s mobile data plan offering to the Polish market. By integrating 1GLOBAL’s eSIM capability into its multi-service app, Revolut’s customers in Poland who signed up to the waitlist can now enjoy bundled mobile plans that include competitively priced domestic data plans starting at zł 25 per month (approx. €6.00 per month) with unlimited calls and texts in Poland and the EU, in just a few taps. For 1GLOBAL, this expansion marks another milestone in the company’s embedded telco services strategy. The services are trusted by more than 4,000 corporate partners across a variety of industries including fi
Dompé Doses First Patients in Europe and US in Phase 3 Study of Isocyclosporin for Atopic Keratoconjunctivitis16.12.2025 13:00:00 CET | Press Release
Dompé, a leading biopharmaceutical company with operations in Italy and the U.S., announced the first patients have been enrolled in a Phase 3 study of Isocyclosporin for the treatment of atopic keratoconjunctivitis (AKC). Isocyclosporin is a dual inhibitor of transient receptor potential (TRP) cation channel, mucolipin subfamily, member 2 (TRPML2) and calcineurin, key regulators of immune and inflammatory response in chronic inflammatory eye diseases. The Phase 3 trial is a multicenter, randomized, double-masked study comparing isocyclosporin against vehicle control in improving ocular signs and symptoms after six weeks of treatment. “This milestone underscores Dompé’s commitment to groundbreaking science with the potential for life-changing patient impact,” said Marcello Allegretti, Chief Scientific Officer at Dompé. “The dual mechanism of isocyclosporin has the potential to redefine treatment and quality of life for patients living with poorly managed AKC. It also marks an important
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom